Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04944121 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of RSLV-132 in Subjects With Long COVID
A Phase 2 study, sponsored by Resolve Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT04944121 is a Phase 2 study that has completed, run by Resolve Therapeutics. The registered enrollment target is 112 participants.
The verdict
NCT04944121, a Phase 2 study, has completed, sponsored by Resolve Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome
Interventions
- DRUG RSLV-132
- DRUG Sodium Chloride 0.9%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-06-25 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04944121
The ClinicalTrials.gov registry entry for NCT04944121 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resolve Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RSLV-132 is the first listed.
NCT04944121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04944121 about?
NCT04944121 is a clinical study titled "Phase 2 Study of RSLV-132 in Subjects With Long COVID". The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome
What is the current status of trial NCT04944121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2021-06-25. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04944121?
The interventions under investigation include: RSLV-132 (DRUG), Sodium Chloride 0.9% (DRUG).
Who is sponsoring clinical trial NCT04944121?
This trial is sponsored by Resolve Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.